MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

Balance Sheets Overview

Current Ratio
2951.71%
Quick Ratio
2951.71%
Cash Ratio
152.74%
Debt to Asset Ratio
5.71%
Unit: Dollar
Assets Breakdown
    • Short-term investments
    • Cash and cash equivalents
    • Prepaid expenses
    • Others
Liabilities Breakdown
    • Additional paid-in capital
    • Accumulated deficit
    • Stock appreciation rights
    • Others
Balance Sheets
2026-06-30
2025-12-31
2025-09-30
2025-06-30
Cash and cash equivalents
11,334,370
3,496,540
1,384,484
1,353,351
Short-term investments
206,396,805
89,509,710
12,502,040
19,266,190
Other receivable
10,912
-
-
-
Prepaid expenses
1,297,590
977,721
967,745
474,628
Total current assets
219,039,677
93,983,971
14,854,269
21,094,169
Other assets
19,500
19,500
21,975
21,975
Total assets
219,059,177
94,003,471
14,876,244
21,116,144
Accounts payable
2,409,190
1,568,944
1,453,102
1,361,911
Accrued expenses
5,011,583
4,861,583
3,736,496
3,772,636
Total current liabilities
7,420,773
6,430,527
5,189,598
5,134,547
Preferred stock value-Preferred Class A
-
-
-
0
Stock appreciation rights
5,080,081
1,060,931
221,107
32,116
Preferred stock value
-
-
-
0
Total liabilities
12,500,854
7,491,458
5,410,705
5,166,663
Common stock, 0.001 par value, 200,000,000 shares authorized, 106,669,846 and 73,333,622 shares issued and outstanding, respectively
106,670
73,333
33,191
33,191
Additional paid-in capital
936,684,992
784,705,878
687,831,786
684,224,232
Accumulated deficit
-730,233,339
-698,267,198
-678,399,438
-668,307,942
Total stockholders equity
206,558,323
86,512,013
9,465,539
15,949,481
Total liabilities and stockholders equity
219,059,177
94,003,471
14,876,244
21,116,144
Unit: Dollar. Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Balance Sheets

Short-term investments$206,396,805 (971.29%↑ Y/Y)Cash and cashequivalents$11,334,370 (737.50%↑ Y/Y)Prepaid expenses$1,297,590 (173.39%↑ Y/Y)Other receivable$10,912 Total current assets$219,039,677 (938.39%↑ Y/Y)Other assets$19,500 (-11.26%↓ Y/Y)Total assets$219,059,177 (937.40%↑ Y/Y)Total liabilities andstockholders equity$219,059,177 (937.40%↑ Y/Y)Total stockholdersequity$206,558,323 (1195.08%↑ Y/Y)Total liabilities$12,500,854 (141.95%↑ Y/Y)Accumulated deficit-$730,233,339 (-9.27%↓ Y/Y)Additional paid-in capital$936,684,992 (36.90%↑ Y/Y)Total currentliabilities$7,420,773 (44.53%↑ Y/Y)Stock appreciationrights$5,080,081 (15717.91%↑ Y/Y)Common stock, 0.001 parvalue, 200,000,000...$106,670 (221.38%↑ Y/Y)Accrued expenses$5,011,583 (32.84%↑ Y/Y)Accounts payable$2,409,190 (76.90%↑ Y/Y)

RELMADA THERAPEUTICS, INC. (RLMD)

RELMADA THERAPEUTICS, INC. (RLMD)